Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ANET NASDAQ:NVDA NASDAQ:REGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANETArista Networks$153.92-0.1%$145.35$83.86▼$179.80$193.82B1.6712.48 million shs10.55 million shsNVDANVIDIA$215.33$196.10$129.16▼$236.54$5.21T2.25164.89 million shs168.17 million shsREGNRegeneron Pharmaceuticals$638.88$731.45$476.49▼$821.11$67.54B0.31.01 million shs994,824 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANETArista Networks0.00%+8.41%-12.92%+20.90%+68.80%NVDANVIDIA0.00%-4.43%+3.38%+12.41%+64.01%REGNRegeneron Pharmaceuticals0.00%-8.50%-14.99%-18.82%+8.59%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANETArista Networks$153.92-0.1%$145.35$83.86▼$179.80$193.82B1.6712.48 million shs10.55 million shsNVDANVIDIA$215.33$196.10$129.16▼$236.54$5.21T2.25164.89 million shs168.17 million shsREGNRegeneron Pharmaceuticals$638.88$731.45$476.49▼$821.11$67.54B0.31.01 million shs994,824 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANETArista Networks0.00%+8.41%-12.92%+20.90%+68.80%NVDANVIDIA0.00%-4.43%+3.38%+12.41%+64.01%REGNRegeneron Pharmaceuticals0.00%-8.50%-14.99%-18.82%+8.59%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANETArista Networks 3.00Buy$181.8418.14% UpsideNVDANVIDIA 3.00Buy$303.2740.84% UpsideREGNRegeneron Pharmaceuticals 2.70Moderate Buy$792.6524.07% UpsideCurrent Analyst Ratings BreakdownLatest NVDA, REGN, and ANET Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2026NVDANVIDIA Citic SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$242.00 ➝ $315.005/22/2026NVDANVIDIA Daiwa Securities GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$215.00 ➝ $255.005/22/2026NVDANVIDIA CICC ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$240.60 ➝ $268.305/21/2026NVDANVIDIA Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOutperform$300.00 ➝ $500.005/21/2026NVDANVIDIA BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$250.00 ➝ $335.005/21/2026NVDANVIDIA EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$352.00 ➝ $413.005/21/2026NVDANVIDIA Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$240.00 ➝ $270.005/21/2026NVDANVIDIA Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold$220.00 ➝ $255.005/21/2026NVDANVIDIA BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight5/21/2026NVDANVIDIA Melius ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$400.005/19/2026REGNRegeneron Pharmaceuticals Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$1,057.00 ➝ $875.00(Data available from 5/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANETArista Networks$9.01B21.52$2.80 per share54.92$10.71 per share14.37NVDANVIDIA$215.94B24.13$4.72 per share45.58$8.08 per share26.65REGNRegeneron Pharmaceuticals$14.92B4.53$41.98 per share15.22$297.23 per share2.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANETArista Networks$3.51B$2.9252.7138.972.3738.32%30.10%19.35%8/4/2026 (Estimated)NVDANVIDIA$120.07B$6.5332.9819.790.6762.97%96.94%72.16%N/AREGNRegeneron Pharmaceuticals$4.50B$41.0415.5715.371.4129.65%13.16%10.17%7/30/2026 (Estimated)Latest NVDA, REGN, and ANET EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2026Q1 2027NVDANVIDIA$1.76$1.87+$0.11$2.39$78.42 billion$81.62 billion5/5/2026Q1 2026ANETArista Networks$0.8080$0.87+$0.0620$0.80$2.62 billion$2.71 billion4/29/2026Q1 2026REGNRegeneron Pharmaceuticals$8.91$9.47+$0.56$6.75$3.48 billion$3.61 billion2/25/2026Q4 2026NVDANVIDIA$1.54$1.62+$0.08$1.76$65.56 billion$68.13 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthANETArista NetworksN/AN/AN/AN/AN/ANVDANVIDIA$0.040.02%+14.87%0.61%1 YearsREGNRegeneron Pharmaceuticals$3.760.59%N/A9.16%N/ALatest NVDA, REGN, and ANET DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/20/2026NVDANVIDIAquarterly$0.250.45%6/4/20266/4/20266/26/20264/29/2026REGNRegeneron Pharmaceuticalsquarterly$0.940.58%5/20/20265/20/20266/4/20262/25/2026NVDANVIDIAquarterly$0.010.02%3/11/20263/11/20264/1/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANETArista NetworksN/A2.832.47NVDANVIDIA0.043.443.24REGNRegeneron Pharmaceuticals0.063.572.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANETArista Networks82.47%NVDANVIDIA65.27%REGNRegeneron Pharmaceuticals83.31%Insider OwnershipCompanyInsider OwnershipANETArista Networks2.70%NVDANVIDIA4.17%REGNRegeneron Pharmaceuticals6.97%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANETArista Networks5,1151.26 billion1.23 billionOptionableNVDANVIDIA42,00024.20 billion23.19 billionOptionableREGNRegeneron Pharmaceuticals15,410105.72 million98.35 millionOptionableNVDA, REGN, and ANET HeadlinesRecent News About These CompaniesGrabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Regeneron Pharmaceuticals, Inc. (REGN)3 hours ago | newsfilecorp.comN5 Cheap NASDAQ Stocks to Buy Right NowMay 25 at 8:51 AM | insidermonkey.comRegeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Simplify Asset Management Inc.May 25 at 5:50 AM | marketbeat.comLevi & Korsinsky Investigates Regeneron Pharmaceuticals, Inc. (REGN) Over Potential Securities Fraud AllegationsMay 24 at 12:12 AM | newsfilecorp.comNRegeneron R&D Updates Test Market View On Long Term Pipeline ValueMay 24 at 9:02 AM | finance.yahoo.comSwedbank AB Boosts Stake in Regeneron Pharmaceuticals, Inc. $REGNMay 24 at 7:01 AM | marketbeat.comRegeneron Pharmaceuticals, Inc. $REGN Shares Purchased by LSV Asset ManagementMay 24 at 5:31 AM | marketbeat.comStocks making big moves this week: Toll Brothers, Booz Allen Hamilton, Strategy, Regeneron, and MicronMay 23 at 6:05 PM | finance.yahoo.com1 of Wall Street’s Favorite Stock with Solid Fundamentals and 2 We QuestionMay 23 at 8:04 AM | finance.yahoo.comABN Amro Investment Solutions Cuts Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGNMay 23 at 3:12 AM | marketbeat.comHere's Why Regeneron (REGN) is a Strong Value StockMay 22 at 10:41 AM | zacks.comOtarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing LossMay 22 at 9:00 AM | finance.yahoo.comAmylyx Stock: Why the Full Pipeline Story Matters (REGN)...May 22 at 7:55 AM | marketbeat.comOtarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing LossMay 22 at 7:00 AM | globenewswire.comLevi & Korsinsky Announces Investigation of Securities Claims Against Regeneron ...May 21, 2026 | caledonianrecord.comCINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGNMay 21, 2026 | prnewswire.comRegeneron Pharmaceuticals Reports Encouraging LINKER-AL2 Trial Results for Lynozyfic® in Systemic AL AmyloidosisMay 21, 2026 | quiverquant.comQLynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain AmyloidosisMay 21, 2026 | finance.yahoo.comLynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain AmyloidosisMay 21, 2026 | globenewswire.comJim Cramer on Regeneron: “There Could Be Some More Downgrades”May 21, 2026 | finance.yahoo.comLevi & Korsinsky Announces Investigation of Securities Claims Against Regeneron Pharmaceuticals, Inc. (REGN)May 21, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines5 Stocks to Buy in May Before the Next AI Surge HitsBy Thomas Hughes | May 1, 2026Beyond NVIDIA: Picks-and-Shovels AI Plays with Strong MomentumBy Chris Markoch | May 10, 2026NVIDIA’s China Connection: Investor Risks With Earnings AheadBy Thomas Hughes | May 5, 2026Years in the Making, AMD’s Upside Movement Has Just BegunBy Thomas Hughes | May 6, 2026Insiders Are Selling Big Tech, But Here Are 3 Reasons You May Not Want ToBy Thomas Hughes | April 28, 2026NVDA, REGN, and ANET Company DescriptionsArista Networks NYSE:ANET$153.92 -0.11 (-0.07%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$153.29 -0.63 (-0.41%) As of 05/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Arista Networks, Inc. engages in the development, marketing, and sale of data-driven, client to cloud networking solutions for data center, campus, and routing environments in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. Its cloud networking solutions consist of Extensible Operating System (EOS), a publish-subscribe state-sharing networking operating system offered in combination with a set of network applications. The company offers data center and cloud networking systems, including newer artificial intelligence (AI) ethernet switching platforms; campus wired and wireless products, and routing systems addressing Core Routing, Edge Routing, Data Center Interconnect (DCI), Multi-cloud and Wide Area Networking (WAN) use cases; and a suite of value-add software solutions that leverage EOS to provide end-to-end orchestration, automation, analytics, network monitoring, and security. It also provides post contract customer support services, such as technical support, hardware repair and replacement parts beyond standard warranty, bug fixes, patches, and upgrade services. The company serves a range of industries comprising internet companies, service providers, financial services organizations, government agencies, media and entertainment companies, telecommunication service providers, and others. It markets and sells its products through distributors, system integrators, value-added resellers, and original equipment manufacturer partners, as well as through its direct sales force. The company was formerly known as Arastra, Inc. and changed its name to Arista Networks, Inc. in October 2008. Arista Networks, Inc. was incorporated in 2004 and is headquartered in Santa Clara, California.NVIDIA NASDAQ:NVDA$215.33 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$214.28 -1.05 (-0.49%) As of 05/22/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.NVIDIA Corporation provides graphics and compute and networking solutions in the United States, Taiwan, China, Hong Kong, and internationally. The Graphics segment offers GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, and solutions for gaming platforms; Quadro/NVIDIA RTX GPUs for enterprise workstation graphics; virtual GPU or vGPU software for cloud-based visual and virtual computing; automotive platforms for infotainment systems; and Omniverse software for building and operating metaverse and 3D internet applications. The Compute & Networking segment comprises Data Center computing platforms and end-to-end networking platforms, including Quantum for InfiniBand and Spectrum for Ethernet; NVIDIA DRIVE automated-driving platform and automotive development agreements; Jetson robotics and other embedded platforms; NVIDIA AI Enterprise and other software; and DGX Cloud software and services. The company's products are used in gaming, professional visualization, data center, and automotive markets. It sells its products to original equipment manufacturers, original device manufacturers, system integrators and distributors, independent software vendors, cloud service providers, consumer internet companies, add-in board manufacturers, distributors, automotive manufacturers and tier-1 automotive suppliers, and other ecosystem participants. NVIDIA Corporation was incorporated in 1993 and is headquartered in Santa Clara, California.Regeneron Pharmaceuticals NASDAQ:REGN$638.88 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$634.44 -4.44 (-0.69%) As of 05/22/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Ross Stores Earnings Beat Sends Stock To New Highs Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins Apparel Earnings Winners and Losers: Ralph Lauren Takes Off SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? The Careful Consumer: What Q1 Earnings Reveal—And Where Cracks May Appear Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
